195 related articles for article (PubMed ID: 31070945)
1. A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma.
Cengiz Seval G; Beksac M
Expert Opin Drug Saf; 2019 Jul; 18(7):563-571. PubMed ID: 31070945
[TBL] [Abstract][Full Text] [Related]
2. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
3. From a Better Understanding of the Mechanisms of Action of Histone Deacetylases Inhibitors to the Progress of the Treatment of Malignant Lymphomas and Plasma Cell Myeloma.
Mihaila RG
Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):283-295. PubMed ID: 28933264
[TBL] [Abstract][Full Text] [Related]
4. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Cavenagh JD; Popat R
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
[TBL] [Abstract][Full Text] [Related]
5. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
6. Deacetylase inhibitors: an advance in myeloma therapy?
Laubach JP; San-Miguel JF; Hungria V; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Alsina M; Richardson PG
Expert Rev Hematol; 2017 Mar; 10(3):229-237. PubMed ID: 28076695
[TBL] [Abstract][Full Text] [Related]
7. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
8. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Moore DC; Arnall JR; Harvey RD
J Oncol Pharm Pract; 2019 Apr; 25(3):613-622. PubMed ID: 30060709
[TBL] [Abstract][Full Text] [Related]
9. The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.
Beider K; Bitner H; Voevoda-Dimenshtein V; Rosenberg E; Sirovsky Y; Magen H; Canaani J; Ostrovsky O; Shilo N; Shimoni A; Abraham M; Weiss L; Milyavsky M; Peled A; Nagler A
Biochem Pharmacol; 2019 Oct; 168():412-428. PubMed ID: 31325448
[TBL] [Abstract][Full Text] [Related]
10. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Richardson PG; Mitsiades CS; Laubach JP; Hajek R; Spicka I; Dimopoulos MA; Moreau P; Siegel DS; Jagannath S; Anderson KC
Leuk Res; 2013 Jul; 37(7):829-37. PubMed ID: 23582718
[TBL] [Abstract][Full Text] [Related]
11. Panobinostat for the management of multiple myeloma.
Sivaraj D; Green MM; Gasparetto C
Future Oncol; 2017 Mar; 13(6):477-488. PubMed ID: 27776419
[TBL] [Abstract][Full Text] [Related]
12. The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Singh A; Patel P; Jageshwar ; Patel VK; Jain DK; Kamal M; Rajak H
Curr Cancer Drug Targets; 2018; 18(8):720-736. PubMed ID: 28669336
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
15. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
16. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Richardson P; Roy A; Acharyya S; Panneerselvam A; Mendelson E; Günther A; Lonial S; Einsele H
Expert Rev Hematol; 2017 Oct; 10(10):933-939. PubMed ID: 28885063
[TBL] [Abstract][Full Text] [Related]
17. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Niesvizky R; Ely S; Mark T; Aggarwal S; Gabrilove JL; Wright JJ; Chen-Kiang S; Sparano JA
Cancer; 2011 Jan; 117(2):336-42. PubMed ID: 20862746
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
